Apraglutide

阿帕拉格鲁肽

Report date: 2025/02/12 10:56:04
NME

Base Information

Drug NameApraglutide
Drug Alias NameGLP2 analougeFE-203799
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 2 receptor agonists
TargetsGlucagon-like peptide 2 receptor
Therapy Area/IndicationsGraft vs Host DiseaseRenal Insufficiency, ChronicHepatic Insufficiency +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[22] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFerring Bv
China Registration ClassN/A

Develop Information

Active CompaniesGlypharmaIronwood Pharmaceuticals IncVectivBio Ag
Inactive CompaniesGlypharma Therapeutic Inc
Active IndicationsRenal Insufficiency, ChronicHepatic InsufficiencyShort Bowel Syndrome
Inactive IndicationsGraft vs Host DiseaseLymphoma, Non-HodgkinHodgkin Disease

Other Information

ATC CodeN/A
Related LinksN/A